ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

MXCT MaxCyte Inc

3.77
-0.06 (-1.57%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
MaxCyte Inc MXCT NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.06 -1.57% 3.77 08:30:10
Open Price Low Price High Price Close Price Previous Close
3.95 3.74 3.95 3.77 3.83
more quote information »

Recent News

Date Time Source Heading
10/4/202422:05GLOBEMaxCyte to Report First Quarter 2024 Financial Results on..
02/4/202423:05GLOBEMaxCyte Signs Strategic Platform License with Be Biopharma..
13/3/202407:05GLOBEMaxCyte Reports Fourth Quarter and Full Year 2023 Financial..
06/3/202408:15EDGAR2Form 8-K - Current report
05/3/202409:39EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/3/202408:05GLOBEMaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023..
27/2/202408:22EDGAR2Form 144 - Report of proposed sale of securities
15/2/202408:26EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
15/2/202404:25EDGAR2Form SC 13G - Statement of acquisition of beneficial..
10/2/202400:05GLOBEMaxCyte to Report Fourth Quarter and Full Year 2023..
02/2/202408:25EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
31/1/202408:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202400:05GLOBEMaxCyte and Wugen Sign Strategic Platform License to..
27/1/202408:45EDGAR2Form 8-K - Current report
27/1/202403:49EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
24/1/202400:05GLOBEMaxCyte Signs Strategic Platform License with Imugene to..
09/1/202408:15EDGAR2Form 8-K - Current report
09/1/202408:05GLOBEMaxCyte Announces Preliminary Unaudited Fourth Quarter and..
05/1/202408:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202400:05GLOBEMaxCyte and Lion TCR form Partnership to Support Global..
02/1/202418:00GLOBEMaxCyte Confirms Appointment of Maher Masoud as President,..
29/12/202308:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202308:30EDGAR2Form 8-K - Current report
12/12/202308:05GLOBEMaxCyte Announces CEO Transition and Updates Revenue..
07/12/202308:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/12/202309:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/11/202308:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/11/202308:32EDGAR2Form 144 - Report of proposed sale of securities
18/11/202308:05EDGAR2Form SC 13G - Statement of acquisition of beneficial..
17/11/202308:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/11/202300:05GLOBEMaxCyte Joins the Alliance for mRNA Medicines (AMM) as a..
09/11/202309:12EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202308:12EDGAR2Form 8-K - Current report
09/11/202308:05GLOBEMaxCyte Reports Third Quarter 2023 Financial Results and..
07/11/202308:05GLOBEMaxCyte to Participate in Two Upcoming Investor Conferences
05/10/202307:14EDGAR2Form 8-K - Current report
05/10/202307:05GLOBEMaxCyte Announces Preliminary Third Quarter 2023 Revenue and..
06/9/202322:05GLOBEMaxCyte Appoints Ali Soleymannezhad as Executive Vice..
05/9/202322:05GLOBEMaxCyte to Participate in Baird Global Healthcare Conference
31/8/202307:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/8/202306:55EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202306:16EDGAR2Form 8-K - Current report
10/8/202306:05GLOBEMaxCyte Reports Second Quarter and Half-Year 2023 Financial..
01/8/202322:05GLOBEMaxCyte Signs Strategic Platform License with Prime Medicine..
29/7/202306:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/7/202322:05GLOBEMaxCyte to Report Second Quarter 2023 Financial Results on..
13/7/202308:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/7/202306:51EDGAR2Form 144 - Report of proposed sale of securities
10/7/202322:05GLOBEMaxCyte and Vittoria Biotherapeutics Sign Strategic Platform..
06/7/202322:05GLOBEMaxCyte Signs Strategic Platform License with Lyell..

Your Recent History

Delayed Upgrade Clock